

Andrew T Stefka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6057075/publications.pdf>

Version: 2024-02-01

5
papers

153
citations

1684188

5
h-index

2053705

5
g-index

5
all docs

5
docs citations

5
times ranked

327
citing authors

#	ARTICLE	IF	CITATIONS
1	Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer Journal, 2021, 11, 19.	6.2	40
2	Potent anti- μ myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Medicine, 2020, 9, 324-334.	2.8	14
3	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood, 2020, 136, 2513-2523.	1.4	56
4	Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT. Journal of Clinical Oncology, 2020, 38, 8513-8513.	1.6	5
5	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2016, 128, 675-675.	1.4	38